11 results on '"Kimyon, Gezmiş"'
Search Results
2. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database.
- Author
-
Ersözlü, Emine Duygu, Ekici, Mustafa, Coşkun, Belkis Nihan, Badak, Suade Özlem, Bilgin, Emre, Kalyoncu, Umut, Yağız, Burcu, Pehlivan, Yavuz, Küçükşahin, Orhan, Erden, Abdulsamet, Solmaz, Dilek, Atagündüz, Pamir, Kimyon, Gezmiş, Beş, Cemal, Çolak, Seda, Mercan, Rıdvan, Kaşifoğlu, Timuçin, Emmungil, Hakan, Kanıtez, Nilüfer Alpay, and Ateş, Aşkın
- Subjects
HEPATITIS B ,DATABASES ,VACCINES ,VIRAL hepatitis ,MICROBIOLOGY ,PHENOMENOLOGICAL biology ,HEPATITIS C ,ANKYLOSIS ,SPONDYLOARTHROPATHIES ,BIOTHERAPY ,RHEUMATOID arthritis ,SYMPTOMS ,DESCRIPTIVE statistics ,DATA analysis software ,RHEUMATISM - Abstract
Objectives: This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments. Patients and methods: The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Türkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used. Results: The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir. Conclusion: The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Eating attitude in patients with rheumatoid arthritis: The relationship between pain, body mass index, disease activity, functional status, depression, anxiety and quality of life.
- Author
-
Yıldırım Keskin, Alev, Şentürk, Sibel, and Kimyon, Gezmiş
- Abstract
The aim of this study is to evaluate the relationship between eating attitude and pain, body mass index, disease activity, functional status, depression, anxiety and quality of life in patients with rheumatoid arthritis (RA). This descriptive and cross-sectional study was conducted with 111 RA patients between January 2021 and May 2021. The Eating Attitudes Test scores of the participants had a positive significant relationship with their Visual Analog Scale scores (r = 0.257), Health Assessment Questionnaire scores (r = 0.221), Beck Anxiety Inventory scores (r = 0.287), Beck Depression Inventory scores (p = 0.224), and Rheumatoid Arthritis Quality of Life Scale scores (r = 0.298) (p < 0.05). This study showed that when the eating attitudes of the RA patients were negative, their anxiety and depression levels increased, and their quality of life was negatively affected. In the positive management of depression and anxiety, by creating treatment guidelines, the moderation of the eating attitudes of patients and increasing their quality of life levels should be ensured. • RA is the most common musculoskeletal disease in the world. • Eating attitude is an important component of the quality of life with RA patients. • Possible causes of eating attitude in RA include pain, limitation of movement, and psychological disorders such as depression and anxiety. • When RA patients have negative eating attitudes, their anxiety and depression levels increase and their quality of life decreases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database
- Author
-
Kanıtez, Nilüfer Alpay, Kiraz, Sedat, Dalkılıç, Ediz, Kimyon, Gezmiş, Mercan, Rıdvan, Karadağ, Ömer, and Beş, Cemal
- Subjects
rheumatoid arthritis ,coronavirus disease 2019 ,Spondyloarthritis ,Society Classification Criteria ,Reliability ,Biological disease-modifying anti-rheumatic drug ,Bath Ankylosing-Spondylitis - Abstract
Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.
- Published
- 2022
5. The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database
- Author
-
Kanitez, Nilufer Alpay, Kiraz, Sedat, Dalkılıç, Ediz, Kimyon, Gezmiş, Mercan, Rıdvan, Karadağ, Ömer, and Beş, Cemal
- Subjects
rheumatoid arthritis ,coronavirus disease 2019 ,Spondyloarthritis ,Society Classification Criteria ,Reliability ,Biological disease-modifying anti-rheumatic drug ,Bath Ankylosing-Spondylitis - Abstract
Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.
- Published
- 2022
6. Is the treatment of inflammatory arthritis different in sickle cell disease?
- Author
-
KİMYON, Gezmiş and İLHAN, Gül
- Subjects
- *
SICKLE cell anemia , *ANTIRHEUMATIC agents , *RHEUMATOID arthritis , *CONNECTIVE tissue diseases , *RHEUMATISM , *INFECTIOUS arthritis - Abstract
Background/aim: Musculoskeletal findings are common in sickle cell patients and may be confused with inflammatory arthritis. In addition, complications such as frequent infections may create difficulties while choosing drugs such as steroids, methotrexate, or anti-TNFs. Our aim is to reveal whether the treatment is different in sickle cell patients with rheumatic diseases such as rheumatoid arthritis. Materials and methods: Patients followed by Rheumatology and Hematology divisions of Hatay Mustafa Kemal University Hospital were retrospectively screened. Excluding patients with musculoskeletal findings associated with sickle cell disease (SCD), patients with chronic or acute inflammatory arthritis were enrolled into study. Demographic data, disease activities, the drugs used, frequency of infection, and sickle cell-related crisis before and after rheumatic disease diagnosis-treatment of the patients were examined. Results: Inflammatory rheumatic disease was detected in 14 of 28 sickle cell patients evaluated in the rheumatology department for musculoskeletal complaints. Twelve of the patients were female and 2 were male. The median duration of rheumatic disease was 27 months (16.5). Eight of these patients had rheumatoid arthritis, 1 had ankylosing spondylitis, reactive arthritis, gout, connective tissue disease, undifferentiated monoarthritis, and 1 patient had undifferentiated oligoarthritis. For rheumatic disease, 11 (78.6%) of the patients were using steroids, 8 (57.1%) hydroxychloroquine, 4 (28.6%) methotrexate and sulfasalazine, 2 (14.3%) leflunomide, 1 (7.1%) anti-TNF (etanercept), and 1 allopurinol and colchicine. The frequency of SCD-related crisis and annual serious infections before and after rheumatic disease treatment were similar (p = 0.31). Conclusion: The clinical manifestations of inflammatory arthritis such as rheumatoid arthritis and sickle cell disease may overlap. The use of drugs such as steroids, methotrexate, or anti-TNF in sickle cell patients with rheumatic disease is the same as in patients without sickle cell disease. However, treatment should be individualized in patients with complications such as infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. ROMATOİD ARTRİTLİ BİREYLERE BAKIM VERENLERİN YÜKÜ VE ALGILADIKLARI SOSYAL DESTEK DÜZEYİ.
- Author
-
KİMYON, Gezmiş, ŞENTÜRK, Sibel, and YILDIRIM KESKİN, Alev
- Abstract
Copyright of Medical Journal of Ankara Training & Research Hospital is the property of Medical Journal of Ankara Training & Research Hospital and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
8. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic.
- Author
-
KALYONCU, Umut, PEHLİVAN, Yavuz, AKAR, Servet, KAŞİFOĞLU, Timuçin, KİMYON, Gezmiş, KARADAĞ, Ömer, DALKILIÇ, Ediz, ERTENLİ, Ali İhsan, KILIÇ, Levent, ERSÖZLÜ, Duygu, BES, Cemal, EMMUNGİL, Hakan, MERCAN, Rıdvan, EDİBOĞLU, Elif Durak, KANITEZ, Nilüfer, BİLGİN, Emre, ÇOLAK, Seda, KOCA, Süleyman Serdar, GÖNÜLLÜ, Emel, and KÜÇÜKŞAHİN, Orhan
- Subjects
COVID-19 pandemic ,RITUXIMAB ,PANDEMICS ,COVID-19 ,PATIENT compliance ,ARTHRITIS ,TERMINATION of treatment ,VISUAL analog scale - Abstract
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Romatoid artrit ve spondiloartritte biyolojik DMARD'lar arasında geçiş ve nedenleri: TReasure gerçek yaşam verileri.
- Author
-
Kalyoncu, Umut, Ertenli, Ali İhsan, Kücükşahin, Orhan, Dalkılıç, Hüseyin Ediz, Erden, Abdulsamet, Bes, Cemal, Kanıtez, Nilüfer Alpay, Kaşifoğlu, Timuçin, Kızılırmak, Pınar, Emmungil, Hakan, Coşkun, Belkis Nihan, Yağız, Burcu, Koca, Süleyman Serdar, Çınar, Muhammet, Ateş, Aşkın, Akar, Servet, Ersözlü, Duygu, Yazısız, Veli, Bilge, Nazife Şule Yaşar, and Kimyon, Gezmiş
- Subjects
DRUG side effects ,PATIENT compliance ,RHEUMATOID arthritis ,BIOCHEMICAL mechanism of action ,FOLLOW-up studies (Medicine) - Abstract
Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
10. Assessment of foot and ankle in female patients with rheumatoid arthritis: a morphological study.
- Author
-
Türkmen, Bilge, Kızılkanat, Emine Döndü, Turhanoğlu, Ayşe Dicle, Kimyon, Gezmiş, and Öğüt, Halil
- Subjects
FOOT ,ANKLE ,RHEUMATOID arthritis ,ANKLE joint ,WOMEN patients ,JOINTS (Anatomy) ,BODY mass index - Abstract
Objective: Rheumatoid arthritis, causes cartilage and bone damage, failure, and systemic complications. The disease affects women 2 to 3 times more often than men. The foot and ankle joints are frequently affected in patients with RA. As the disease progresses, the frequency of foot involvement increases, and at any time during the course of the disease, approximately 90% of cases develop foot-related complaints. In this study, it was aimed to investigate the effects of RA disease on foot morphometry by comparing the foot and ankle morphometric measurements of female patients with RA and healthy individuals. Methods: Necessary permissions and ethics committee approvals were obtained to measure individuals. In our study, 60 female patients with a diagnosis of RA and 60 healthy controls who were similar in age, gender, body mass index and dominant extremity of these patients were evaluated. Length (foot length, lateral foot length, toes length, etc.), height (caput ossis metatarsi I and V heights, malleolus medialis and lateralis heights, etc.), circumference measurements (bimalleolar circumference, etc.), goniometric measurements (1st and 5th metatarsophalangeal angle) and diameter measurements (foot metatarsal diameter, etc.) were performed on all individuals participating in the study. Body weight and height measurements were made with a height scale. Foot morphometric measurements were made using an inflexible tape measure, goniometer and anthropometric set. Measurements were made on individuals with the right dominant lower extremity and all measurements were taken from the right lower extremities of the subjects. Results: Among the morphological measurements, foot length, lateral foot length, bimalleolar circumference values, caput ossis metatarsi I and V heights were statistically significantly higher in RA patients compared to healthy individuals (p<0.05). The lengths of the 2nd, 3rd and 5th toes, and the medial malleolus and lateralis height values were statistically significantly higher in healthy individuals than in RA patients (p<0.05). In goniometric measurements, the first metatarsophalangeal angle was found to be statistically significantly higher in RA patients compared to healthy individuals (p<0.05). Conclusion: We think that RA disease causes changes in foot morphology, and that the anthropometric data in our study can be a reference for the design and modification of shoes, orthotics and prostheses for women with RA in our country and may provide benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2022
11. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
- Author
-
Orhan Küçükşahin, Servet Akar, Emel Gönüllü, Duygu Ersözlü, Sedat Kiraz, Gezmiş Kimyon, Hakan Emmungil, Umut Kalyoncu, Ali İhsan Ertenli, Nihan Coşkun, Emre Bilgin, Rıdvan Mercan, Yavuz Pehlivan, Omer Karadag, Hüseyin Dalkiliç, Cemal Bes, Süleyman Serdar Koca, Burcu Yağız, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Seda Colak, Elif Durak Ediboglu, Levent Kilic, İç Hastalıkları, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut, Pehlivan, Yavuz, Akar, Servet, Kaşifoğlu, Timuçin, Kimyon, Gezmiş, Karadağ, Ömer, Dalkılıç, Ediz, Ertenli, Ali İhsan, Kılıç, Levent, Ersözlü, Duygu, Beş, Cemal, Emmungil, Hakan, Mercan, Rıdvan, Ediboğlu, Elif Durak, Bilgin, Emre, Çolak, Seda, Koca, Süleyman Serdar, Gönüllü, Emel, Küçükşahin, Orhan, Coşkun, Nihan, Yağız, Burcu, Kiraz, Sedat, Koç University Hospital, and School of Medicine
- Subjects
rheumatoid arthritis ,Male ,Bath ankylosing spondylitis disease activity index ,Inflammatory arthritis ,polymerase chain reaction ,very elderly ,health status ,Disease ,Arthritis, Rheumatoid ,Cohort Studies ,rituximab ,adalimumab ,Pandemic ,middle aged ,disease modifying antirheumatic drug ,Health Assessment Questionnaire ,Prospective Studies ,Registries ,golimumab ,Aged, 80 and over ,register ,Ankylosing Spondylitis Disease Activity Score ,secukinumab ,adult ,medication compliance ,Simplified Disease Activity Index ,Biologic DMARDs ,General Medicine ,spondyloarthritis ,Middle Aged ,cohort analysis ,aged ,female ,spondylarthritis ,Rheumatoid arthritis ,drug withdrawal ,Antirheumatic Agents ,young adult ,Rituximab ,Female ,biologic DMARDs ,medicine.drug ,prospective study ,Adult ,medicine.medical_specialty ,abatacept ,hydroxychloroquine ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Visual analogue scale ,COVID-19 ,Spondyloarthritis ,salazosulfapyridine ,methotrexate ,Article ,Medication Adherence ,tocilizumab ,coronavirus disease 2019 ,Young Adult ,remission ,Internal medicine ,medicine ,DAS28 ,Humans ,human ,Pandemics ,Aged ,leflunomide ,business.industry ,SARS-CoV-2 ,pandemic ,questionnaire ,General and internal medicine ,visual analog scale ,medicine.disease ,major clinical study ,Discontinuation ,certolizumab pegol ,Bath ankylosing spondylitis functional index ,antirheumatic agent ,observational study ,erythrocyte sedimentation rate ,business ,infliximab ,Crohn Disease Activity Index ,etanercept ,disease activity - Abstract
Background/aim: to evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: a total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: a total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored., Hacettepe Rheumatology Society
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.